We are studying the safety and tolerability of roginolisib combined with ruxolitinib for patients with myelofibrosis who haven't responded to other treatments. The trial also looks at symptom improvement and changes in spleen size.
Health conditions and diseases that the clinical trial is designed to study and treat.
Myelofibrosis (MF) is a serious bone marrow disorder that disrupts the body's normal production of blood cells, leading to severe anemia, fatigue, and an enlarged spleen. In cases where it is unresponsive to JAK inhibitors, treatment options may be limited.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
